'/%3E%3C/svg%3E%0A){kind=small}
The latest news, insights and resources from Prothena
From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer’s disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer’s disease.
© 2025 Prothena | Terms of Use | Privacy Policy | Cookie Policy |
The purpose of this resource is to provide information to US healthcare professionals (HCPs) about Prothena’s investigational drug candidates.
This resource contains medical and scientific information related to Prothena’s products and/or uses that have not been approved by any regulatory authority (e.g., FDA, EMA).
If you are a patient or caregiver, please discuss any medical or treatment questions with your healthcare provider.
All Prothena drugs (wholly-owned or partnered) referenced herein are investigational drugs and not approved by any regulatory authority.
